ImmunoGenesis Unveils Promising Results for IMGS-001 at ASCO 2025 Meeting

ImmunoGenesis to Present Key Updates on IMGS-001 at ASCO 2025

ImmunoGenesis, a forward-thinking clinical-stage biotech firm, has made headlines as it prepares to present a Trial in Progress poster for its innovative immunotherapy, IMGS-001, at the prestigious 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Scheduled from May 30 to June 3, this event serves as a platform for unveiling critical findings and advancements in the field of oncology.

Overview of IMGS-001

IMGS-001 is a pioneering dual-specific PD-L1/PD-L2 antibody designed with a unique cytotoxic killing mechanism. This innovative therapeutic approach aims to target “immune-excluded” cancers—tumors that resist current immunotherapy treatments. Charles Schweizer, PhD and Senior Vice President of Clinical Development at ImmunoGenesis, emphasized the significance of this study in advancing treatment options for these challenging cancers.

Clinical Study Details

The Phase 1a/1b clinical trial (NCT06014502) is currently ongoing, involving dosage escalation and expansion phases that will assess the safety, pharmacokinetics, and preliminary anti-tumor activity of IMGS-001 in adult patients grappling with locally advanced or metastatic solid tumors resistant to conventional treatments.

Approximately 25 patients will participate in the Phase 1a segment, with Phase 1b potentially enrolling up to 250 individuals. Notably, the initial three of five planned dose cohorts have been effectively completed without encountering dose-limiting toxicities (DLTs), and enrollment is currently underway for the fourth cohort (10 mg/kg).

James Barlow, President and CEO, expressed optimism regarding the trial's results thus far. The preliminary doses have been well-tolerated and have shown early indications of anti-tumor activity in patients who have previously not responded to standard care. He articulated the hope that IMGS-001 could become a significant treatment option for immune-excluded tumors.

Presentation Details at ASCO

Title of Presentation:

A Phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of IMGS-001 in Patients with relapsed or refractory advanced solid tumors.

Abstract Reference:

TS2686 | Poster Board #324a

Track:

Developmental Therapeutics—Immunotherapy

Location:

Hall A - Posters and Exhibits | On Demand

Time:

June 2, 2025, 1:30 PM – 4:30 PM CDT

Future Prospects and About ImmunoGenesis

ImmunoGenesis is committed to reshaping the landscape of immuno-oncology by addressing the core mechanisms of immune resistance. Being currently evaluated in clinical trials, IMGS-001 is a cytotoxic, dual-specific PD-L1/PD-L2 antibody targeted at cold tumors, which represent over half of all cancer cases. This innovative approach could provide a much-needed solution for overcoming immune exclusion and stimulating a robust immune response.

With a strong focus on transforming treatment methods for advanced cancers, ImmunoGenesis embodies the future of oncology treatment pathways. To learn more about their revolutionary work, visit ImmunoGenesis.

As the clinical trial progresses, the medical community eagerly awaits data that could potentially revolutionize treatments for patients facing difficult-to-treat cancers.